Axcelis Technologies (NASDAQ: ACLS) reported Q2 EPS of $0.39, $0.12 better than the analyst estimate of $0.27. Revenue for the quarter came in at $123 million versus the consensus estimate of $116.18 million.

President and CEO Mary Puma commented, "We are very pleased with our strong second quarter performance. Customer interest in our Purion platform remains strong, as evidenced by demo activity and evaluation system placements for both our Purion base platform and our new Purion product extensions. With the most innovative implant product line available, a broad and diverse customer base, a strong balance sheet and a dedicated team of employees, Axcelis has the building blocks to navigate these uncertain times and ultimately drive growth and market leadership in ion implantation."

GUIDANCE:

Axcelis Technologies sees Q3 2020 revenue of $110 million, versus the consensus of $110 million.

For earnings history and earnings-related data on Axcelis Technologies (ACLS) click here.